Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score‐matched study from the FRANCOGYN group
BJOG: An International Journal of Obstetrics & Gynaecology · 2023
DOI: 10.1111/1471-0528.17524 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2023. Verfasst von Henri Wohrer und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecological Oncological and Breast Surgery, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Européen Georges-Pompidou, Pa…. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Cytoreduction Surgical Procedures, Ovarian Neoplasms, Peritoneal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To compare survival and morbidity rates between primary cytoreductive surgery (pCRS) and interval cytoreductive surgery (iCRS) for epithelial ovarian cancer (EOC), using a propensity score.
Design
We conducted a propensity score‐matched cohort study, using data from the FRANCOGYN cohort.
Setting
Retrospective, multicentre study of data from patients followed in 15 French department specialized in the treatment of ovarian cancer. Sample Patients included were those with International Federation of Gynaecology and Obstetrics (FIGO) stage III or IV EOC, with peritoneal carcinomatosis, having undergone CRS.
Methods
The propensity score was designed using pre‐therapeutic variables associated with both treatment allocation and overall survival (OS). Main Outcome Measures The primary outcome was OS. Secondary outcomes included recurrence‐free survival (RFS), quality of CRS and other variables related to surgical morbidity.
Results
A total of 513 patients were included. Among these, 334 could be matched, forming 167 pairs. No difference in OS was found (hazard ratio, HR = 0.8, p = 0.32). There was also no difference in RFS (median = 26 months in both groups) nor in the rate of CRS leaving no macroscopic residual disease (pCRS 85%, iCRS 81.4%, p = 0.76). The rates of gastrointestinal tract resections, stoma, postoperative complications and hospital stay were significantly higher in the pCRS group.
Conclusions
Analysis of groups of patients made comparable by propensity score matching showed no difference in survival, but lower postoperative morbidity in patients treated with iCRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynaecological Oncological and Breast Surgery, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Européen Georges-Pompidou, Paris, France.
- INSERM UMR-S 1124, University of Paris Cité, Centre Universitaire des Saint-Père, Paris, France.
- Department of Gynecologic and Oncologic Surgery and Obstetrics, Lyon Sud University Hospital, Hospices Civils de Lyon, Université Lyon 1, Lyon, France.
- CHU Lille, Service de Chirurgie Gynécologique, Université Lille, Lille, France.
- Department of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, Reims, France.
- Department of Gynaecology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
ORCID-Profile: Henri Wohrer
Zitieren
APA
Wohrer, H., Koual, M., Bentivegna, E., Benoit, L., Metairie, M., Bolze, P. A., Kerbage, Y., Raimond, E., Akladios, C., Carcopino, X., Canlorbe, G., Uzan, J., Lavoue, V., Mimoun, C., Huchon, C., Koskas, M., Costaz, H., Margueritte, F., Dabi, Y., …, & Azaïs, H. (2023). Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score‐matched study from the FRANCOGYN group. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17524
Vancouver
Wohrer H, Koual M, Bentivegna E, Benoit L, Metairie M, Bolze PA, et al. Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score‐matched study from the FRANCOGYN group. BJOG: An International Journal of Obstetrics & Gynaecology. 2023. doi:10.1111/1471-0528.17524
BibTeX
@article{Wohrer2023,
author = {Wohrer, Henri and Koual, Meriem and Bentivegna, Enrica and Benoit, Louise and Metairie, Marie and Bolze, Pierre-Adrien and Kerbage, Yohan and Raimond, Emilie and Akladios, Cherif and Carcopino, Xavier and Canlorbe, Geoffroy and Uzan, Jennifer and Lavoue, Vincent and Mimoun, Camille and Huchon, Cyrille and Koskas, Martin and Costaz, Hélène and Margueritte, François and Dabi, Yohann and Touboul, Cyril and Bendifallah, Sofiane and Ouldamer, Lobna and Delanoy, Nicolas and Nguyen-Xuan, Huyen-Thu and Bats, Anne-Sophie and Azaïs, Henri},
title = {Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score‐matched study from the FRANCOGYN group},
journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
year = {2023},
doi = {10.1111/1471-0528.17524}
}
EUVIMED